Alzheimer Europe wrote to EU Vice-President for Democracy and Demography, Dubravka Šuica, and Health Commissioner, Stella Kyriakides, asking for dementia to be prioritised within EU policies, including the EU4Health programme. We have received a joint response from both offices.
Alzheimer Europe’s 
On 8 July, the biotechnology company Biogen completed the submission of a biologics license application to the US Food and Drug Administration (FDA) for aducanumab as a treatment for Alzheimer’s disease (AD). Biogen requested a priority, six-month review, which has since been granted by the FDA, meaning a response will be given by 7 March 2021.
On 28 July 2020, following engagement with its national members, research funders and industry partners, Alzheimer Europe issued a position statement highlighting the pressure on dementia research as a result of COVID-19. To address these issues, the position statement sets out a number of recommendations aimed at research funders and research institutions.
The 2020 Lancet Commission on dementia prevention, intervention and care identifies 12 modifiable risk factors that may account for 40% of dementia cases. Theoretically, modification of these risk factors could prevent or delay the development of dementia.
Registration is now open for the 30th Alzheimer Europe Conference (#30AEC), taking place online from 20 to 22 October. Take advantage of the early bird registration fees until 15 September 2020, with a reduced registration fee of EUR 75 instead of EUR 125.
This newsletter received funding under an operating grant from the European Union’s Health Programme (2014-2020).